Ipsen buys Memo Therapeutics for €200M upfront, gaining kidney-transplant drug potravitug in its second deal this week.
Erik van den Berg, Memo Therapeutics CEO
July 1, 2026 07:12 AM EDT
Deals
Ipsen to scoop up Memo Therapeutics and its kidney infection drug
Ayisha Sharma
Ipsen will pay $450 million upfront to buy Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed…
The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a…
Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s…
In this week’s edition of InnovationRx, we look at AbbVie’s new megadeal, an agentic AI startup saving Medicare $2 million a…
Cartesian’s $150M financing; Editas Medicine’s money moves
Agios licenses Oscotec’s immune thrombocytopenia drug; CEPI funds three Ebola vaccine candidates; Skyhawk shares Huntington's…
